Chronic kidney disease (CKD) is a global public health problem. Progression to kidney failure is a devastating outcome that all efforts aim to prevent. GLP-1 receptor agonists (GLP-1 RAs), developed initially for the management of type 2 diabetes mellitus (DM), have been shown to have both cardio- and kidney- protective effects in recent trials. The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial was a double blind, randomized, controlled trial of Semaglutide conducted in patients with type 2 DM, who were at risk of CKD progression1.
3 days ago
2 